Lista de obras -

A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia

artículo científico publicado en 2009

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

artículo científico publicado en 2006

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

artículo científico publicado en 2003

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

artículo científico publicado en 2010

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

artículo científico publicado en 2007

Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia

artículo científico publicado en 2013

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia ⬇️

artículo científico publicado el 29 de noviembre de 2010

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment

artículo científico publicado en 2009

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

artículo científico publicado en 2009

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

artículo científico publicado en 2005

Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients

artículo científico publicado en 2008

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

artículo científico publicado en 2009

Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation

artículo científico publicado en 2006

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia

artículo científico publicado en 2014

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia ⬇️

artículo científico publicado el 19 de septiembre de 2011

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia ⬇️

artículo científico publicado el 13 de junio de 2011

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

artículo científico publicado en 2005

Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival

artículo científico publicado en 2015

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

artículo científico publicado en 2004

Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia ⬇️

artículo científico publicado el 29 de julio de 2013

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

artículo científico publicado en 2011

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years

artículo científico publicado en 2009

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia ⬇️

artículo científico publicado el 12 de julio de 2011

Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes

artículo científico publicado en 2012

Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience

artículo científico publicado en 2006

Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors

artículo científico publicado en 2007

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

artículo científico publicado en 2014

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

scientific article published on 14 April 2008

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia

artículo científico publicado en 2013

Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma

scientific article published on 29 December 2008

Phase I trial of nelarabine in indolent leukemias

artículo científico publicado en 2008

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia

artículo científico publicado en 2008

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

artículo científico publicado en 2003

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

artículo científico publicado en 2003

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

artículo científico publicado en 2007

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia

artículo científico publicado en 2013

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

artículo científico publicado en 2008

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

artículo científico publicado en 2014

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

artículo científico publicado en 2014

The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease

artículo científico publicado en 2002

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

artículo científico publicado en 2007

The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia

artículo científico publicado en 2011

microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival

artículo científico publicado en 2010

p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy

artículo científico publicado en 2009

Lista de obras de

A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia ⬇️

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia ⬇️

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia ⬇️

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia ⬇️

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia ⬇️

Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes

Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience

Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia

Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma

Phase I trial of nelarabine in indolent leukemias

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia

microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival

p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy